Search

Your search keyword '"Porayko, M."' showing total 130 results

Search Constraints

Start Over You searched for: Author "Porayko, M." Remove constraint Author: "Porayko, M."
130 results on '"Porayko, M."'

Search Results

1. T06.01.12 OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY

2. Hemobilia following Percutaneous Liver Biopsy in the Setting of Malignancy (with Video): Diagnosis and Management of a Rare Cause of Upper Gastrointestinal Bleeding

5. Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study

6. LP17 : Novel approach for the prevention of recurrent hepatitis C in liver transplant recipients: Preliminary results from ongoing phase III trial with civacir®

24. Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning.

25. Role of Endoscopic Retrograde Cholangiopancreatography after Orthotopic Liver Transplantation.

29. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

30. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.

31. An Unusual Cause of a Liver Mass in a Woman.

33. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.

34. Recurrent autoimmune hepatitis after orthotopic liver transplantation.

35. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease.

36. Intragraft localization of activated nuclear factor kappaB in recurrent hepatitis C virus disease following liver transplantation.

37. The economic impact of cytomegalovirus infection after liver transplantation.

38. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation.

39. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis.

40. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension.

41. Recurrence of primary sclerosing cholangitis following liver transplantation.

42. CD40L (CD154) expression in human liver allografts during chronic ductopenic rejection.

43. Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency.

44. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.

45. Optimal timing of liver transplantation for primary biliary cirrhosis.

46. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506).

47. Liver dysfunction and parenteral nutritional therapies.

48. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.

49. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group.

50. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.

Catalog

Books, media, physical & digital resources